LabCorp (LH) Q2 2026 Earnings Beat: $4.99 EPS, Guidance Raised
As seen on the 24/7 Wall St. homepage on July 30, 2026.
LabCorp crushed Q2 earnings with $4.99 EPS, clearing estimates by 4.6%, and immediately raised full-year guidance as both diagnostics and biopharma lab services delivered organic growth above 5%. The diagnostics giant signaled margin expansion across both segments and confidence to sustain momentum through year-end.
Continue ReadingShow less
LabCorp reported Q2 2026 earnings per share of $4.99, clearing the consensus estimate of $4.77 by roughly 4.6%. That result is also a meaningful step up from each of the prior seven quarters charted, which ranged from $3.45 to $4.35, underscoring an accelerating trend rather than a one-quarter spike. Revenue came in at $3.73 billion, edging past expectations of $3.71 billion by about 0.5%.
Both the diagnostics and biopharma lab services segments posted organic growth above 5%, and management flagged margin expansion across each business. That combination of top-line momentum and widening margins gave the company enough conviction to lift its full-year guidance immediately following the report, a signal that the Q2 performance is seen as durable rather than seasonal.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
Investors will be watching whether the organic growth rates in both segments hold above that 5% threshold as the year progresses and whether the promised margin expansion materializes in Q3 results. The raised guidance sets a higher bar heading into the second half of 2026.
Mentioned: LH